Cannabinoid glycosides:<i>In vitro</i>production of a new class of cannabinoids with improved physicochemical properties

Hardman, Janee' M.; Brooke, Robert T.; Zipp, Brandon J.

doi:10.1101/104349

Cited by 12 publications

(13 citation statements)

References 47 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vitality Biopharma (Los Angeles, CA, USA) have proposed an invention that has led to several cannabinoid glycoside prodrugs (cannabosides) being obtained and characterized [ 72 , 73 ] ( Figure 2 ). This method grants the gastro-intestinal targeting of THC, while avoiding narcotic effects.…”

Section: Current Drug Dosage Forms and Novel Delivery Systemsmentioning

confidence: 99%

Cannabinoid Delivery Systems for Pain and Inflammation Treatment

Bruni¹,

et al. 2018

View full text Add to dashboard Cite

There is a growing body of evidence to suggest that cannabinoids are beneficial for a range of clinical conditions, including pain, inflammation, epilepsy, sleep disorders, the symptoms of multiple sclerosis, anorexia, schizophrenia and other conditions. The transformation of cannabinoids from herbal preparations into highly regulated prescription drugs is therefore progressing rapidly. The development of such drugs requires well-controlled clinical trials to be carried out in order to objectively establish therapeutic efficacy, dose ranges and safety. The low oral bioavailability of cannabinoids has led to feasible methods of administration, such as the transdermal route, intranasal administration and transmucosal adsorption, being proposed. The highly lipophilic nature of cannabinoids means that they are seen as suitable candidates for advanced nanosized drug delivery systems, which can be applied via a range of routes. Nanotechnology-based drug delivery strategies have flourished in several therapeutic fields in recent years and numerous drugs have reached the market. This review explores the most recent developments, from preclinical to advanced clinical trials, in the cannabinoid delivery field, and focuses particularly on pain and inflammation treatment. Likely future directions are also considered and reported.

show abstract

Section: Current Drug Dosage Forms and Novel Delivery Systemsmentioning

confidence: 99%

Cannabinoid Delivery Systems for Pain and Inflammation Treatment

Bruni¹,

et al. 2018

View full text Add to dashboard Cite

show abstract

“…and was recently deployed for the production of novel cannabinoid glycosides [37]. This method allows for the characterization of GTs that can then be introduced to a production host for large scale biosynthesis.…”

Section: Advances In Cell-free Platforms Have Enabled the Interrogatimentioning

confidence: 99%

New frontiers: harnessing pivotal advances in microbial engineering for the biosynthesis of plant-derived terpenoids

Belcher

Mahinthakumar

Keasling

2020

Current Opinion in Biotechnology

View full text Add to dashboard Cite

“…The glycosylation of cannabinoids represents another promising opportunity for the biosynthesis of unnatural cannabinoids with improved water solubility, bioavailability, and site-specific drug targeting. For instance, it was shown for the first time that the UDP-glycosyltransferases from Stevia rebaudiana and Oryza sativa were able to produce cannabinoid mono-, di-, tri-, and tetraglycosides in vitro [64].…”

Section: Cannabinoidsmentioning

confidence: 99%

Medicinal Plants: Guests and Hosts in the Heterologous Expression of High-Value Products

Vasil'ev

2021

Planta Med

View full text Add to dashboard Cite

Medicinal plants play an important dual role in the context of the heterologous expression of high-value pharmaceutical products. On the one hand, the classical biochemical and modern omics approaches allowed for the discovery of various genes encoding biosynthetic pathways in medicinal plants. Recombinant DNA technology enabled introducing these genes and regulatory elements into host organisms and enhancing the heterologous production of the corresponding secondary metabolites. On the other hand, the transient expression of foreign DNA in plants facilitated the production of numerous proteins of pharmaceutical importance. This review summarizes several success stories of the engineering of plant metabolic pathways in heterologous hosts. Likewise, a few examples of recombinant protein expression in plants for therapeutic purposes are also highlighted. Therefore, the importance of medicinal plants has grown immensely as sources for valuable products of low and high molecular weight. The next step ahead for bioengineering is to achieve more success stories of industrial-scale production of secondary plant metabolites in microbial systems and to fully exploit plant cell factoriesʼ commercial potential for recombinant proteins.

show abstract

Cannabinoid glycosides:In vitroproduction of a new class of cannabinoids with improved physicochemical properties

Cited by 12 publications

References 47 publications

Cannabinoid Delivery Systems for Pain and Inflammation Treatment

Cannabinoid Delivery Systems for Pain and Inflammation Treatment

New frontiers: harnessing pivotal advances in microbial engineering for the biosynthesis of plant-derived terpenoids

Medicinal Plants: Guests and Hosts in the Heterologous Expression of High-Value Products

Contact Info

Product

Resources

About